A cannabis cultivation license in Switzerland allows qualified individuals and businesses to legally grow cannabis either for medical use under Swissmedic’s two-stage authorization system or for government-approved pilot programs overseen by the Federal Office of Public Health (FOPH). For hands-on guidance, Cannaspire’s Cannabis consultants work with operators at every stage.
Since May 15, 2021, Switzerland has operated under Article 8a of the amended Federal Narcotics Act, which permits time-limited scientific pilot trials for non-medical cannabis use. Medical cannabis cultivation requires both an establishment license and an individual cultivation license issued by Swissmedic.
At the same time, Switzerland continues to evaluate broader adult-use legalization. Several legislative proposals remain under parliamentary review, informed by data gathered through ongoing pilot programs.
In mid-February 2025, the National Council’s Social Security and Health Committee endorsed a preliminary draft bill to legalize adult-use cannabis. A public consultation period followed and concluded on December 1, 2025.
The draft legislation, referred to as the Cannabis Products Act (Cannabisproduktegesetz), is now under review. Its framework is directly informed by findings published in Analysis of Results from Cannabis Pilot Trials in Swiss Cities, Part I (2023 to mid-2024), which addresses product standards, retail design, taxation, and public-health safeguards.
Switzerland currently operates a three-tier licensing framework that separates medical production, pilot-program cultivation, and low-THC hemp:
The establishment license is the foundation for lawful medical cannabis cultivation. It authorizes license holders to acquire seeds and controlled narcotic substances.
Applicants must:
Fees & inspections:
Swissmedic reviews the application and documentation. The relevant canton conducts an on-site inspection.
After the establishment license is approved, the business must apply for individual cultivation licenses through Swissmedic’s NDS-Web Portal.
Each authorization applies to a single cultivation cycle, meaning a new license is required for every grow batch.
This requirement applies to commercial operators, not personal or informal cultivation.
Applications must include:
Required cultivation details:
Cultivation for pilot trials under Article 8a of the Narcotics Act requires an exceptional license from the FOPH. Applications are submitted jointly with the organization responsible for the pilot trial.
Required information includes:
Cannabis containing less than 1% total THC does not require authorization from the FOPH for cultivation or handling. These products fall under standard agricultural regulations rather than narcotics control.
However, businesses involved in manufacturing, processing, or distribution of CBD products may still require cantonal or Swissmedic licenses depending on their activities.
All applicants must first register in the Swiss commercial register. Prior to submitting any license applications, businesses must establish compliant storage facilities and appoint a qualified Responsible Person.
The Responsible Person must either:
Applications are submitted through Swissmedic with full supporting documentation. Forms are available at www.swissmedic.ch/betm.
Once all documents are received and the cantonal inspection is completed, Swissmedic’s processing period is approximately 10 weeks.
The canton conducts an on-site inspection to verify compliance with storage, security, and diversion-prevention requirements. Inspection outcomes directly influence Swissmedic’s licensing decision.
With an establishment license in place, cultivators submit individual cultivation applications via the NDS-Web Portal. Each application must correspond to a specific grow cycle and include detailed cultivation and supply documentation.
Medical cannabis operations must maintain full traceability from seed to sale and comply with quality assurance standards. Post-harvest activities such as manufacturing and distribution require GMP or GDP certification under the Narcotics Control Ordinance.
Pilot trial cannabis must meet product requirements under Article 9 of the Ordinance on Pilot Trials, including:
Swiss authorities have evaluated international standards such as GACP and Canadian Good Production Practices when developing Swiss quality frameworks.
Switzerland’s cannabis pilot trials operate under a federally authorised framework overseen by the Federal Office of Public Health (FOPH), allowing adult participants resident in the relevant canton to purchase regulated cannabis products through approved points of sale, with all supply chains subject to mandatory track-and-trace monitoring for scientific and public-health evaluation.
Cultivators must partner with one of the authorized municipal pilot trials. Some cities, including Zurich, are operating pilot programs scheduled to run through 2028, creating longer-term participation opportunities.
Each operation must appoint a Responsible Person and deputy who meet education requirements and submit recent criminal background checks.
All storage must comply with Article 54 of the Narcotics Control Ordinance and prevent unauthorized access or diversion.
Licensed cultivators must implement systems that track cannabis from seed sourcing through final distribution, ensuring consistency, safety, and regulatory transparency.
Written supply agreements are mandatory for individual cultivation licenses and ensure cannabis is distributed exclusively through authorized channels.
Processing timelines typically extend several months when inspections and individual cultivation approvals are included.
Draft legislation currently under review proposes a federally regulated commercial cannabis market in which cultivation would require federal authorization, while retail would be managed through cantonal concession systems. The draft framework also sets limits on vertical integration between producers and retailers and would allow limited home cultivation for personal use, subject to defined plant and possession thresholds.
Licensed cultivators are subject to ongoing reporting, documentation, and record-keeping obligations and may be inspected by cantonal authorities and Swissmedic to verify compliance with licensing requirements. Failure to meet these obligations can result in licence conditions being amended, suspended, or revoked.
Is cannabis cultivation legal in Switzerland in 2026?
Yes, for licensed medical cultivation and approved pilot programs. CBD hemp below 1% THC remains unlicensed.
Can I grow cannabis at home without a license?
No. cannabis with 1% THC or higher is regulated under the Narcotics Act, and cultivation is generally prohibited and punishable unless authorised.
How long does it take to get licensed?
Establishment license processing takes about 10 weeks after inspection, with total timelines often extending several months. Pair your launch with cannabis regulatory compliance consulting so nothing slips after opening.
Minnesota cannabis buildout guide: the 18-month clock, zoning and local registration, security rules, Metrc onboarding, and OCM inspection readiness.
What it takes to fund a Virginia cannabis business before the February 2027 application window — capital stack, investor structures, CCA disclosure rules, and 280E math.
How hemp operators move into licensed cannabis before the federal 0.4 mg THC cap takes effect: the four realistic paths, what transfers, and what to do in the next 90 days.
